Edmondo Robinson
CARRIAGE SERVICESAbout Edmondo Robinson
Dr. Edmondo Robinson, age 49, is an independent director of Carriage Services (CSV) since 2024 and currently serves as Chair of the Audit Committee (appointed February 24, 2025), and member of the Compensation and Corporate Governance Committees. He is Professor of Internal Medicine and Oncologic Science at the University of South Florida (Morsani College of Medicine), and previously served as SVP & Chief Digital Officer at Moffitt Cancer Center (2019–2024) and Chief Transformation Officer/SVP of Consumerism at ChristianaCare (2017–2019). His education credentials include a BS (UC San Diego), MD (UCLA), MBA with healthcare emphasis (Wharton), and a master’s in health policy research (University of Pennsylvania); he is also an ACP fellow, SHM senior fellow, and former Aspen Health Innovators Fellow .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Moffitt Cancer Center | Senior Vice President & Chief Digital Officer | 2019–2024 | Founded and led the Center for Digital Health; drove digital innovation initiatives |
| ChristianaCare | Chief Transformation Officer & SVP of Consumerism | 2017–2019 | Led transformation efforts and consumer/digital strategies |
External Roles
| Organization | Market | Role | Tenure | Notes |
|---|---|---|---|---|
| University of South Florida, Morsani College of Medicine | Academic | Professor of Internal Medicine & Oncologic Science | Current | Academic appointment |
| Ardent Health Services (ARDT) | NYSE | Director | Since 2022 | Only CSV director serving on another public company board |
| University of Vermont Health Network | Non-profit | Trustee | Current | Governance/trustee role |
| Agency for Healthcare Research and Quality (AHRQ) National Advisory Council | Federal advisory | Chair | Current | Advisory leadership role |
Board Governance
| Item | Detail |
|---|---|
| Independence | Independent director; all Audit Committee members are independent per NYSE and SEC Rule 10A-3 |
| Committees | Audit (Chair), Compensation (Member), Corporate Governance (Member) |
| Audit Chair appointment | Elected Chair of Audit Committee on February 24, 2025 |
| Audit Committee expertise | Board determined Dr. Robinson has necessary accounting/financial expertise; designated an “audit committee financial expert” along with other listed directors |
| Meeting cadence & attendance | Board held 12 regular meetings in 2024; all then-current directors attended all Board meetings. Audit Committee held 5 regular meetings and Compensation Committee held 6, with full attendance by then-current members |
Committee Summary
| Committee | Role | Start Date | 2024 Meetings | Attendance |
|---|---|---|---|---|
| Audit | Chair | Feb 24, 2025 | 5 | All members present at all meetings |
| Compensation | Member | 2024 | 6 | All members present at all meetings |
| Corporate Governance | Member | 2024 | Not disclosed | Membership as of Record Date |
Fixed Compensation
| Component | Amount | Form | Timing/Notes |
|---|---|---|---|
| Independent Director Annual Retainer | $150,000 | Cash or unrestricted common stock (director election) | Paid quarterly ($37,500); policy revised April 2, 2024 following Pearl Meyer benchmarking |
| Board Chair Additional Retainer | $20,000 | Cash or stock | Paid quarterly; for independent Chair |
| Audit Committee Chair Retainer | $20,000 | Cash or stock | Paid quarterly |
| Compensation Committee Chair Retainer | $15,000 | Cash or stock | Paid quarterly |
| Corporate Governance Committee Chair Retainer | $10,000 | Cash or stock | Paid quarterly |
| New Independent Director One-time Grant | $25,000 | Cash or unrestricted stock | Granted upon election; vests immediately |
| Dr. Robinson 2024 Compensation – Cash Fees | $10,312 | Cash | Actual 2024 |
| Dr. Robinson 2024 Compensation – Fees Paid in Stock | $15,382 | Unrestricted stock | Actual 2024 |
| Dr. Robinson 2024 Compensation – Stock Awards | $24,985 | Unrestricted stock | Includes new director grant; actual 2024 |
| Dr. Robinson 2024 Compensation – Total | $50,679 | Mixed cash/stock | Actual 2024 |
| New Director Grant Detail (Robinson) | 765 shares | Unrestricted stock | Granted Oct 30, 2024 at $32.66; vested immediately |
Performance Compensation
| Metric Category | Status | Notes |
|---|---|---|
| Director performance-based pay (PSUs/Options) | Not applicable | Non-employee director pay consists of retainers in cash or unrestricted stock; no disclosed performance metrics or option awards for directors |
Other Directorships & Interlocks
| Entity | Role | Start Date | Interlocks/Conflicts |
|---|---|---|---|
| Ardent Health Services (ARDT) | Director | 2022 | CSV notes no other directors serve on public boards; Robinson is the only one. No compensation committee interlocks or substantial business dealings requiring related-party disclosure reported |
| University of Vermont Health Network | Trustee | Not disclosed | Non-profit governance role; no related-party transactions reported |
| AHRQ National Advisory Council | Chair | Not disclosed | Federal advisory role; no related-party transactions reported |
Expertise & Qualifications
- Designated audit committee financial expert; deemed to have necessary accounting/financial expertise to chair Audit Committee .
- 25+ years in digital health, healthcare delivery, innovation; led creation of digital health programs/technologies and value-based care consumer strategies aligning with CSV’s innovation and capital allocation objectives .
- Academic and professional credentials: BS (UCSD), MD (UCLA), MBA (Wharton, healthcare emphasis), master’s in health policy research (Penn); ACP fellow; SHM senior fellow; Aspen Health Innovators Fellow .
Equity Ownership
| Holder | Common Stock | Stock Options (Exercisable within 60 days) | Total Beneficial Ownership | % of Common Stock |
|---|---|---|---|---|
| Dr. Edmondo Robinson | 1,151 | — | 1,151 | * (indicates <1%) |
- Ownership measurement date: March 14, 2025 (Record Date). “Percent” asterisk indicates less than 1% ownership as per proxy table .
- Stock Ownership Guidelines: Directors must own stock equal to 1x annual retainer; compliance required within later of 3 years from April 2, 2024 or 3 years after joining the Board .
- Vested/Unvested: New director grant of 765 shares vested immediately (Oct 30, 2024) .
- Pledging/Hedging: No pledging/hedging disclosures for Dr. Robinson noted; proxy reports no related party transactions since January 1, 2024 .
Insider Transactions (Director)
| Date | Transaction | Shares | Price | Vesting | Source |
|---|---|---|---|---|---|
| Oct 30, 2024 | New independent director one-time grant | 765 | $32.66 | Vested immediately | Proxy footnote (Director Compensation Table) |
Section 16(a) filings were timely for fiscal 2024 per company review; no related-party transactions reported since January 1, 2024 .
Governance Assessment
- Independence & Board Effectiveness: Robinson strengthens independent oversight as Audit Chair; Board determined he has accounting/financial expertise and designated him an audit committee financial expert; Audit Committee independence and literacy affirmed .
- Attendance & Engagement: Board and relevant committees reported full attendance by then-current members in 2024, indicating active engagement; Board held 12 meetings, Audit 5, Compensation 6 .
- Compensation Alignment: Director pay is fixed retainer (cash or unrestricted stock) with ability to elect stock, enhancing alignment; share ownership guidelines set at 1x the annual retainer with a reasonable compliance window .
- Other Public Board & Overboarding: CSV emphasizes focus on directors not serving on numerous public boards; Robinson is the only CSV director with an additional public board (Ardent). This single external public directorship is noted without additional interlocks or conflicts requiring disclosure .
- Conflicts/Related Party: No reportable related-party transactions since January 1, 2024; Compensation Committee members (including Robinson) had no substantial business dealings with CSV requiring disclosure .
- Signals for Investor Confidence: Governance refresh (committee chairs, new directors), majority voting for directors with resignation policy in uncontested elections, and clear related-party review procedures administered by the Audit Committee all support governance quality and risk oversight .